Disrupting Pharma's Maladaptive Inertia
Recently, Health Decisions CEO Michael Rosenberg had an opportunity to sit down with Dr. Adam Goldstein and Dr. Adam Zolotor on Here's to Your Health, UNC Family Medicine's radio talk... Read more
Announcing a New Standard for Running Today's Adaptive Clinical Trials
We’d like to extend our congratulations to Dr. Michael Rosenberg, our CEO and resident author, on the release of his new book: The Agile Approach to Adaptive Research: Optimizing... Read more
New FDA guidelines: Can device makers learn the rules and innovate at the same time?
After a year of legislation and congressional speculation insulating medical device makers from lawsuits and economic penalties, it looks as though the FDA will replace its favor with the same... Read more
Discussing a new model for global research with Applied Clinical Trials
We recently got a chance to chat with Applied Clinical Trials’ Lisa Henderson about our new network approach to global clinical development. Coming face to face with breaking industry... Read more
Efficiency vs. Innovation: Finding a Way to Achieve Both at Once
The whole country has its ear turned toward Washington, eagerly listening for how we’ll be affected by the myriad proposed disruptions to healthcare policy. Notwithstanding the legitimate... Read more
An Ounce of Prevention: Risk Mitigation in Pharma Development
The difficulty of getting oncology products to market was emphasized in a recent New York Times article , along with a good lesson about needlessly risky study execution. The article... Read more
Will Eli Lilly's new structure protect it from the market? As long as innovation and efficiency remain the focus.
Lilly’s renovation plans are big news in pharma this week—starting January 1, 2010, the company will adopt a majorly restructured operating model in hopes of reducing cost, boosting... Read more
Boeing's 787 Dreamliner and what Pharma can learn from it
The New York Times ’ recent article on Boeing’s delays getting its new 787 Dreamliner off the ground should hit close to home for many of us in the drug development industry.... Read more
Implementing adaptive trials that don't violate the sacred tenets of design
There's a great article in The Scientist this month that asks: "A once-rare type of clinical trial that violates one of the sacred tenets of trial design is taking off, but is it worth the... Read more
Adaptive offers a promising solution to enrollment issues
Monday's New York Times article, "Lack of Study Volunteers Hobbles Cancer Fight," describes how the ongoing difficulty of recruiting patients for oncology trials is eroding scientists' chances... Read more
